Axitinib-Induced Repigmentation of Grey Hair in a Patient With Metastatic Renal Cell Carcinoma

A 6-month treatment with axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, led to the repigmentation of grey hair in a patient with metastatic renal cell carcinoma. The patient's grey scalp and moustache hair turned black without the use of hair dye or other medications, starting at the hairline and moving to the occipital region. This case is notable as it is the first documented instance of axitinib-induced hair repigmentation, although other tyrosine kinase inhibitors have been associated with similar effects.